CN100388951C - 饮食食品组合物和利用该组合物的饮食方法 - Google Patents
饮食食品组合物和利用该组合物的饮食方法 Download PDFInfo
- Publication number
- CN100388951C CN100388951C CNB99108490XA CN99108490A CN100388951C CN 100388951 C CN100388951 C CN 100388951C CN B99108490X A CNB99108490X A CN B99108490XA CN 99108490 A CN99108490 A CN 99108490A CN 100388951 C CN100388951 C CN 100388951C
- Authority
- CN
- China
- Prior art keywords
- food
- carbohydrate
- flour
- class
- fat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 65
- 235000013305 food Nutrition 0.000 title claims abstract description 56
- 238000000034 method Methods 0.000 title claims abstract description 22
- 235000005911 diet Nutrition 0.000 title claims description 22
- 230000000378 dietary effect Effects 0.000 title 2
- 235000013312 flour Nutrition 0.000 claims abstract description 43
- 150000001720 carbohydrates Chemical class 0.000 claims abstract description 33
- 235000014633 carbohydrates Nutrition 0.000 claims abstract description 30
- 235000008429 bread Nutrition 0.000 claims abstract description 15
- 241000209140 Triticum Species 0.000 claims abstract description 14
- 235000021307 Triticum Nutrition 0.000 claims abstract description 14
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 12
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 12
- 241000196324 Embryophyta Species 0.000 claims abstract description 10
- 238000002360 preparation method Methods 0.000 claims abstract description 9
- 235000015173 baked goods and baking mixes Nutrition 0.000 claims abstract description 4
- 239000000835 fiber Substances 0.000 claims description 29
- 239000003795 chemical substances by application Substances 0.000 claims description 28
- 230000037213 diet Effects 0.000 claims description 20
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 18
- 210000000582 semen Anatomy 0.000 claims description 16
- 239000008280 blood Substances 0.000 claims description 12
- 210000004369 blood Anatomy 0.000 claims description 12
- JKXCZYCVHPKTPK-UHFFFAOYSA-N hydrate;trihydrochloride Chemical compound O.Cl.Cl.Cl JKXCZYCVHPKTPK-UHFFFAOYSA-N 0.000 claims description 12
- 235000018102 proteins Nutrition 0.000 claims description 11
- 239000002671 adjuvant Substances 0.000 claims description 10
- 230000000578 anorexic effect Effects 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 10
- 235000013399 edible fruits Nutrition 0.000 claims description 9
- 235000012149 noodles Nutrition 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 9
- 235000013311 vegetables Nutrition 0.000 claims description 9
- -1 chlorine azepine Di-potassium Chemical compound 0.000 claims description 8
- 235000019197 fats Nutrition 0.000 claims description 8
- 241000251468 Actinopterygii Species 0.000 claims description 7
- 108010068370 Glutens Proteins 0.000 claims description 7
- 108010073771 Soybean Proteins Proteins 0.000 claims description 7
- 235000013336 milk Nutrition 0.000 claims description 7
- 239000008267 milk Substances 0.000 claims description 7
- 210000004080 milk Anatomy 0.000 claims description 7
- 235000019710 soybean protein Nutrition 0.000 claims description 7
- DBGIVFWFUFKIQN-UHFFFAOYSA-N (+-)-Fenfluramine Chemical compound CCNC(C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-UHFFFAOYSA-N 0.000 claims description 6
- 102000002322 Egg Proteins Human genes 0.000 claims description 6
- 108010000912 Egg Proteins Proteins 0.000 claims description 6
- 229960004890 diethylpropion Drugs 0.000 claims description 6
- XXEPPPIWZFICOJ-UHFFFAOYSA-N diethylpropion Chemical compound CCN(CC)C(C)C(=O)C1=CC=CC=C1 XXEPPPIWZFICOJ-UHFFFAOYSA-N 0.000 claims description 6
- 229960001582 fenfluramine Drugs 0.000 claims description 6
- 125000002346 iodo group Chemical group I* 0.000 claims description 6
- 235000013339 cereals Nutrition 0.000 claims description 5
- 210000002969 egg yolk Anatomy 0.000 claims description 5
- DBGIVFWFUFKIQN-VIFPVBQESA-N (+)-Fenfluramine Chemical compound CCN[C@@H](C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-VIFPVBQESA-N 0.000 claims description 4
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 claims description 4
- 244000046052 Phaseolus vulgaris Species 0.000 claims description 4
- 235000010627 Phaseolus vulgaris Nutrition 0.000 claims description 4
- 229940049706 benzodiazepine Drugs 0.000 claims description 4
- 229960004597 dexfenfluramine Drugs 0.000 claims description 4
- 235000013345 egg yolk Nutrition 0.000 claims description 4
- 235000013372 meat Nutrition 0.000 claims description 4
- 235000019737 Animal fat Nutrition 0.000 claims description 3
- 235000014121 butter Nutrition 0.000 claims description 3
- 101100381997 Danio rerio tbc1d32 gene Proteins 0.000 claims description 2
- 241000287828 Gallus gallus Species 0.000 claims description 2
- 229920001202 Inulin Polymers 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 claims description 2
- 101100381999 Mus musculus Tbc1d32 gene Proteins 0.000 claims description 2
- 235000010489 acacia gum Nutrition 0.000 claims description 2
- 239000001785 acacia senegal l. willd gum Substances 0.000 claims description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 2
- 229940029339 inulin Drugs 0.000 claims description 2
- 238000012423 maintenance Methods 0.000 claims description 2
- 210000004681 ovum Anatomy 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 235000015927 pasta Nutrition 0.000 abstract description 3
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 208000020442 loss of weight Diseases 0.000 abstract 1
- 235000014594 pastries Nutrition 0.000 abstract 1
- 239000003153 chemical reaction reagent Substances 0.000 description 17
- 230000037396 body weight Effects 0.000 description 15
- 230000000694 effects Effects 0.000 description 13
- 239000002775 capsule Substances 0.000 description 11
- 239000008194 pharmaceutical composition Substances 0.000 description 11
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- 208000008589 Obesity Diseases 0.000 description 8
- 229930003270 Vitamin B Natural products 0.000 description 7
- 235000019156 vitamin B Nutrition 0.000 description 7
- 239000011720 vitamin B Substances 0.000 description 7
- 206010033307 Overweight Diseases 0.000 description 6
- 229960001264 benfluorex Drugs 0.000 description 6
- CJAVTWRYCDNHSM-UHFFFAOYSA-N benzoic acid 2-[1-[3-(trifluoromethyl)phenyl]propan-2-ylamino]ethyl ester Chemical compound C=1C=CC=CC=1C(=O)OCCNC(C)CC1=CC=CC(C(F)(F)F)=C1 CJAVTWRYCDNHSM-UHFFFAOYSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 6
- 229960003105 metformin Drugs 0.000 description 6
- 235000020824 obesity Nutrition 0.000 description 6
- FKJIJBSJQSMPTI-CAOXKPNISA-M sodium;(4r)-4-[(5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-3,7,12-trioxo-1,2,4,5,6,8,9,11,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl]pentanoate Chemical compound [Na+].C1CC(=O)C[C@H]2CC(=O)[C@H]3[C@@H]4CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]4(C)C(=O)C[C@@H]3[C@]21C FKJIJBSJQSMPTI-CAOXKPNISA-M 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N EtOH Substances CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 108010019160 Pancreatin Proteins 0.000 description 5
- 239000003925 fat Substances 0.000 description 5
- 235000021312 gluten Nutrition 0.000 description 5
- 235000009200 high fat diet Nutrition 0.000 description 5
- 229940055695 pancreatin Drugs 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 4
- MFOCDFTXLCYLKU-CMPLNLGQSA-N Phendimetrazine Chemical compound O1CCN(C)[C@@H](C)[C@@H]1C1=CC=CC=C1 MFOCDFTXLCYLKU-CMPLNLGQSA-N 0.000 description 4
- 229930003268 Vitamin C Natural products 0.000 description 4
- 229930003427 Vitamin E Natural products 0.000 description 4
- 210000000941 bile Anatomy 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 229960000436 phendimetrazine Drugs 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 235000021147 sweet food Nutrition 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
- RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 description 4
- 229960001661 ursodiol Drugs 0.000 description 4
- 235000019154 vitamin C Nutrition 0.000 description 4
- 239000011718 vitamin C Substances 0.000 description 4
- 235000019165 vitamin E Nutrition 0.000 description 4
- 229940046009 vitamin E Drugs 0.000 description 4
- 239000011709 vitamin E Substances 0.000 description 4
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 235000001412 Mediterranean diet Nutrition 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 3
- 208000022531 anorexia Diseases 0.000 description 3
- 206010061428 decreased appetite Diseases 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 230000000871 hypocholesterolemic effect Effects 0.000 description 3
- 239000003701 inert diluent Substances 0.000 description 3
- 229940126701 oral medication Drugs 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000002516 radical scavenger Substances 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 235000019155 vitamin A Nutrition 0.000 description 3
- 239000011719 vitamin A Substances 0.000 description 3
- 229940045997 vitamin a Drugs 0.000 description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 208000000412 Avitaminosis Diseases 0.000 description 2
- 229940123208 Biguanide Drugs 0.000 description 2
- 208000027219 Deficiency disease Diseases 0.000 description 2
- 229940123457 Free radical scavenger Drugs 0.000 description 2
- 206010020565 Hyperaemia Diseases 0.000 description 2
- 206010021135 Hypovitaminosis Diseases 0.000 description 2
- 206010025476 Malabsorption Diseases 0.000 description 2
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 102000014171 Milk Proteins Human genes 0.000 description 2
- 108010011756 Milk Proteins Proteins 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 239000000219 Sympatholytic Substances 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 235000002201 avitaminosis Nutrition 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 150000004283 biguanides Chemical class 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 235000013351 cheese Nutrition 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 235000014510 cooky Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 229950005627 embonate Drugs 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 235000021239 milk protein Nutrition 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229910052711 selenium Inorganic materials 0.000 description 2
- 239000011669 selenium Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 230000000948 sympatholitic effect Effects 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 208000030401 vitamin deficiency disease Diseases 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- BLGXFZZNTVWLAY-SCYLSFHTSA-N yohimbine Chemical compound C1=CC=C2C(CCN3C[C@@H]4CC[C@H](O)[C@@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-SCYLSFHTSA-N 0.000 description 2
- RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 description 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- 239000004925 Acrylic resin Substances 0.000 description 1
- 229920000178 Acrylic resin Polymers 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 208000006770 Ascorbic Acid Deficiency Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 240000000902 Diospyros discolor Species 0.000 description 1
- 235000003115 Diospyros discolor Nutrition 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- YPFUOQUNLGJCBM-UHFFFAOYSA-N N1C=CC=CC=C1.[Cl] Chemical compound N1C=CC=CC=C1.[Cl] YPFUOQUNLGJCBM-UHFFFAOYSA-N 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 206010029400 Nicotinic acid deficiency Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000002141 Pellagra Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 241000282894 Sus scrofa domesticus Species 0.000 description 1
- 239000000150 Sympathomimetic Substances 0.000 description 1
- 244000098345 Triticum durum Species 0.000 description 1
- 235000007264 Triticum durum Nutrition 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 206010047623 Vitamin C deficiency Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003627 anti-cholesterol Effects 0.000 description 1
- 230000002961 anti-hyperuricemic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 235000015179 biltong Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- HPWQPIAUFOFUJW-UHFFFAOYSA-N chlorosylbenzene Chemical compound O=ClC1=CC=CC=C1 HPWQPIAUFOFUJW-UHFFFAOYSA-N 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- FCBNNTXINJPXSP-UHFFFAOYSA-N dimethylcarbamothioylsulfanyl n,n-dimethylcarbamodithioate;6-methyl-n-phenyl-2,3-dihydro-1,4-oxathiine-5-carboxamide Chemical compound CN(C)C(=S)SSC(=S)N(C)C.S1CCOC(C)=C1C(=O)NC1=CC=CC=C1 FCBNNTXINJPXSP-UHFFFAOYSA-N 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000007046 ethoxylation reaction Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000002366 lipolytic effect Effects 0.000 description 1
- 235000004213 low-fat Nutrition 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 230000002911 mydriatic effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 239000000734 parasympathomimetic agent Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 208000010233 scurvy Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000000276 sedentary effect Effects 0.000 description 1
- 230000011218 segmentation Effects 0.000 description 1
- 125000003748 selenium group Chemical group *[Se]* 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000010902 straw Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 230000001975 sympathomimetic effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A21—BAKING; EDIBLE DOUGHS
- A21D—TREATMENT, e.g. PRESERVATION, OF FLOUR OR DOUGH, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS; PRESERVATION THEREOF
- A21D2/00—Treatment of flour or dough by adding materials thereto before or during baking
- A21D2/08—Treatment of flour or dough by adding materials thereto before or during baking by adding organic substances
- A21D2/24—Organic nitrogen compounds
- A21D2/26—Proteins
- A21D2/261—Animal proteins
-
- A—HUMAN NECESSITIES
- A21—BAKING; EDIBLE DOUGHS
- A21D—TREATMENT, e.g. PRESERVATION, OF FLOUR OR DOUGH, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS; PRESERVATION THEREOF
- A21D2/00—Treatment of flour or dough by adding materials thereto before or during baking
- A21D2/08—Treatment of flour or dough by adding materials thereto before or during baking by adding organic substances
- A21D2/24—Organic nitrogen compounds
- A21D2/26—Proteins
- A21D2/264—Vegetable proteins
-
- A—HUMAN NECESSITIES
- A21—BAKING; EDIBLE DOUGHS
- A21D—TREATMENT, e.g. PRESERVATION, OF FLOUR OR DOUGH, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS; PRESERVATION THEREOF
- A21D2/00—Treatment of flour or dough by adding materials thereto before or during baking
- A21D2/08—Treatment of flour or dough by adding materials thereto before or during baking by adding organic substances
- A21D2/36—Vegetable material
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
- A23L33/22—Comminuted fibrous parts of plants, e.g. bagasse or pulp
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
- A23L7/10—Cereal-derived products
- A23L7/109—Types of pasta, e.g. macaroni or noodles
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
- A23L7/10—Cereal-derived products
- A23L7/115—Cereal fibre products, e.g. bran, husk
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
- A23L7/10—Cereal-derived products
- A23L7/198—Dry unshaped finely divided cereal products, not provided for in groups A23L7/117 - A23L7/196 and A23L29/00, e.g. meal, flour, powder, dried cereal creams or extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Pediatric Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Botany (AREA)
- Zoology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Noodles (AREA)
- Bakery Products And Manufacturing Methods Therefor (AREA)
- Grain Derivatives (AREA)
- Cereal-Derived Products (AREA)
- Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
- General Preparation And Processing Of Foods (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明涉及以粉末形式存在的食物组合物,该组合物含有至少50%的蛋白质、低于15%的碳水化合物和35-50%的植物纤维,优选碳水化合物含量低于10%,更优选低于5%;该组合物可在食品的制备中用作小麦面粉的替代物,例如面条、面包、面包棒、烤制食品和面制糕点,并且该组合物构成了改善人体体形方法的基础,该方法通过有益于美学的体重减轻的方式来实现。
Description
技术领域
本发明涉及食品部门和饮食工业。
特别是,本发明涉及一种一般可替代谷类粉特别是可替代小麦粉的食品组合物,以及可用该组合物制备的食品。
本发明还涉及控制个人的体重的方法。
背景技术
众所周知,在发达国家甚至在发展中国家,即使没有肥胖问题的超重者其比例也正在不断地和逐渐地增加。这对个人健康和各个国家的总的健康支出都将具有重要影响,因为已充分证明肥胖或甚至是超重是心血管病和新陈代谢疾病如心肌梗塞、中风、二型糖尿病等的重要致病原因。
营养学家建议的对抗和/或防止超重的饮食方法主要包括低热量或低脂肪的饮食习惯。
另一种广泛建议甚至被大众媒体(杂志,电视等)所提倡的控制体重的方法是采用著名的“地中海饮食”,该饮食基于富含复合碳水化合物的食物如面条、米饭、面包等。
然而事实是,低热量饮食和地中海饮食的广泛使用事实上并没有使肥胖或超重人口的比例产生任何统计学上的重要变化;该比例反而在逐渐增加。
低热量饮食事实上在降低体重方面能有某些暂时的效果,但该效果不能长时间保持,不仅因为其通常使身体虚弱,而且因为经过长时间后由于食物滋味的单调而被人们所拒绝(人们本质上喜欢肉、鱼和绿叶蔬菜)。
所谓“地中海饮食”事实上只适合于从事精力充沛的体力活动的人保持合适的体重和合适的体形。基本上从事久坐工作的人当它们的食物基本基于碳水化合物时相反会使体重增加和脂肪积累。
发明内容
本发明所要解决的问题是提供一种饮食/食品,该饮食/食品可使肥胖或只是超重的人通过消耗过量的脂肪重新恢复其理想的体重并长时间保持该理想体重。所有这些不需要人们必须接受低热量饮食并忍受长时间缺乏食物如一般面条、面包和烤制品的痛苦。
这一问题按照本发明通过一种食品组合物而得到解决,该食品组合物为含有至少50%的蛋白质、15%以下的碳水化合物和30-50%、优选35-50%的植物纤维的粉末形式。
按照本发明的饮食其特征在于全部或部分地剔除超重人饮食中的碳水化合物。所述类型的饮食是本领域一般都知道的生酮饮食。生酮饮食总是能满足人的食欲并总是能减轻体重,但也能产生一些副作用,如高尿酸血、高血糖、高血胆甾醇、高甘油三酯、肝-胰病变、精神病等等。
因此,本发明所要解决的进一步的问题是提供一种用于防止并处理生酮饮食中如一种按照本发明的生酮饮食中会发生的上述副作用的组合物。
所述进一步的问题通过权利要求书中引用的药物组合物得到解决。
按照本发明的食品组合物的碳水化合物含量优选为小于10%,有利的是小于5%。
蛋白质优选的是选自包括谷蛋白、大豆蛋白类、奶蛋白类特别是不含乳糖的豆奶、从肉或干鱼或熏鱼得到的动物蛋白类、蛋清和蛋黄、小麦蛋白类、麦芽、稻谷芽、大豆蛋白、豌豆蛋白在内的组中。
植物纤维优选的是选自包括谷类植物纤维类特别是小麦、玉蜀黍和燕麦,小麦、玉蜀黍和大豆类,蔬菜纤维类特别是西红柿、菠菜,菊粉,阿拉伯胶,以及水果纤维类特别是橙类和苹果类在内的组中。
按照本发明的食品组合物另外还可以含有植物脂肪特别是来自椰子和大豆的脂肪,以及动物脂类特别是蛋黄、奶油和全奶的脂类。所述食品组合物可进一步含有面粉特别是选自由嫩小麦粉和鼓小麦粉组成的组中的面粉。
蛋白质和植物纤维都以细分的形式使用并且以适当的比例混合,以制成在制备食品如面条、面包、面包棒、烤制品和糕点中可以用作小麦粉的替代物的面粉。
本发明还涉及一种通过获得有益于美学的体重减轻来改善人的体形的方法,该方法包括去除所述人的饮食中所有碳水化合物基食物,而代之以用上面描述的面粉获得的食物。
有利的是,这种方法规定开始时使用具有尽可能低的碳水化合物含量的面粉,无论如何该含量不大于5重量%。
尽管含有最少量的碳水化合物,但按照本发明的面粉中总有一定量的碳水化合物存在,因为商业上可获得的植物纤维中总是含有少量残余的糖类物质。一旦达到了所希望的美学效果,便可在第二阶段按照本发明的方法使用具有较高碳水化合物含量的面粉。优选的是应该使用碳水化合物含量低于15%的面粉。
在该方法的可描述为保持阶段的第三阶段中,面粉的碳水化合物含量可以进一步提高,但是不能超过20重量%的界限。这保证能保持所取得的美学效果,同时在饮食中可以导入较多的种类。
另外,上述饮食的效果可以通过与用于治疗肥胖的辅剂结合的方式得到改善。所述辅剂含有至少一种选自由镇静-安血剂、厌食剂和脂肪分解剂所组成的组中的辅剂。
镇静-安血剂优选的是一种苯并二氮杂,最优选的是7-氯-2,3-二氢-2-氧基-5-苯基-1H-1,4-苯并二氮杂(氯氮杂二钾盐)。对于一个体重大约为70kg的成人优选的氯氮杂二钾盐的剂量是每天0.5mg至10mg。
厌食剂优选的是选自由2-二乙胺基苯基苯基酮的盐酸盐(安非拉酮氯化水合物)、氟苯丙胺氯化水合物和D-氟苯丙胺氯化水合物所组成的组中。对于一个体重大约为70kg的成人优选的厌食剂的剂量是每天2mg至35mg。
脂肪分解剂优选的是选自由三氧化物(tiroxine)的类似物所组成的组中,最优选的脂肪分解剂是3,5,3′-三碘代三重乙酸(triioditiroaceticacid)。对于一个体重大约为70kg的成人优选的脂肪分解剂的剂量是每天0.2mg至0.8mg。
因此本发明方法规定,想减轻体重的人应从其饮食中去除所有富含碳水化合物的食物如一般的面包、面条、甜食和烤制食品,并用上述面粉所得的“临摹”食品代替,在甜食的情况下用非糖的甜料代替。
上面所述的面粉可按照与小麦面粉相同的方式使用。例如为了制面包,可将这种面粉与水和酵母并加入可能的盐、猪油、橄榄油或其它可选择的组分制成生面团,让其发酵,然后在炉子中用烤制面包相同的温度进行焙烤。
同样,为了制备甜食如馅饼、饼干等,将该面粉与黄油或人造黄油或类似油脂、鸡蛋、酵母(如果需要)以及其它可选择的组分制成生面团,加入非糖甜料(如糖精)并按照与传统甜食相同的方式在炉子中焙烤。
对于那些想通过本发明的下述方法保持其理想体重的人,还应该对糖果、甜饮料等中富含的水果的消费有自制力。
如上所述,还提供一种药物组合物用于防止或治疗生酮饮食中可能产生的副作用。
具体地说,所述药物组合物A含有一种降血胆甾醇试剂,一种降甘油三酯试剂,一种脂肪分解和蛋白质分解试剂,一种降血糖试剂和一种促进胆液排泄试剂。
降血胆甾醇试剂优选的是选自由2-[α-甲基-(三氟甲基)苯乙胺]-乙醇苯甲酸酯(苯氟雷司)和3-α-7B-二羟基-5B-胆-24烷酸(熊去氧胆酸)所组成的组中。
降甘油三酯试剂优选的是2-[α-甲基-(三氟甲基)苯乙胺]-乙醇苯甲酸酯(苯氟雷司),它优选的是以相对于组合物A的总量的7-23重量%的通用量存在。
脂肪分解和蛋白分解试剂优选的是全冷冻干燥的胰腺(胰酶IXF.U.),它优选的是以相对于组合物A的总量的27-43重量%的量存在。
降血糖试剂优选的是选自由双胍类物质所组成的组中,所述双胍类物质优选的是1,1-二甲基双胍(甲福明),它优选的是以相对于组合物A的总量的36-41重量%的量存在。
促进胆液排泄试剂优选的是选自由3,7,12-三糖-5B-胆-24-烷酸(脱氢胆酸钠)和3-α-7B-二羟基-5B-胆-24-烷酸(熊去氧胆酸)所组成的组中。当脱氢胆酸钠存在时,它优选的是以相对于组合物A的总量的9-14重量%的量存在。当熊去氧胆酸存在时,它优选的是以相对于组合物A的总量的14-17重量%的量存在。
该组合物还可以另外含有一种降尿酸血试剂。所述试剂优选的是由积雪草纯化的三萜烯,它优选的是以相对于组合物A的总量的0.04∶1至0.5∶1的重量比存在。
另外,该组合物可以含有一种自由基清除剂。优选的所述清除剂是硒,它优选的是可以以相对于组合物A的总量的0.0001∶1至0.0003∶1的重量比存在。
该组合物还可以含有一种交感神经阻滞剂。所述阻滞剂优选的是17-α-羟基-育亨烷-16-α-羧酸甲酯(可立宁),它优选的是可以以相对于组合物A的总量的0.0009∶1至0.007∶1的重量比存在。
该组合物还可以另外含有一种拟交感神经试剂。所述试剂选自由苯双甲吗啉重酒石酸和苯双甲吗啉双羟萘酸酯所组成的组中,它优选的是可以以相对于组合物A的总量的0.004∶1至0.1∶1的重量比存在。
此外,该组合物还可以含有至少一种维生素,优选的所述至少一种维生素选自由维生素A,维生素B1,维生素B6,维生素E和维生素C所组成的组中。
当维生素A存在时,其比例为相对于组合物A的总量的0.4∶1至1.8∶1的重量比。
当维生素B1存在时,其比例为相对于组合物A的总量的0.002∶1至0.007∶1的重量比。
当维生素B6存在时,其比例为相对于组合物A的总量的0.04∶1至0.2∶1的重量比。
当维生素E存在时,其比例为相对于组合物A的总量的0.09∶1至1∶1的重量比。
当维生素C存在时,其比例为相对于组合物A的总量的0.09∶1至0.3∶1的重量比。
该组合物A还可以进一步含有至少一种选自由镇静-安血剂、厌食剂和脂肪分解剂所组成的组中的饮食辅剂。
镇静-安血剂优选的是一种苯并二氮杂,最优选的是7-氯-2,3-二氢-2-氧基-5-苯基-1H-1,4-苯并二氮杂(氯氮杂二钾盐),它优选的是以相对于组合物A的总量的0.0004∶1至0.03∶1的重量比存在。
厌食剂优选的是选自由2-二乙胺基苯基苯基酮盐酸盐(安非拉酮氯化水合物)、氟苯丙胺氯化水合物和D-氟苯丙胺氯化水合物所组成的组中。所述厌食剂优选的是以相对于组合物A的总量的0.002∶1至0.1∶1的重量比存在。
脂肪分解剂优选的是选自由三氧化物的类似物所组成的组中,最优选的脂肪分解剂是3,5,3′-三碘代三重乙酸,它优选的是以相对于组合物A的总量的0.0002∶1至0.003∶1的重量比存在。
所有上述能够组成组合物A的试剂一般都是可商购的。
特别是安非拉酮氯化水合物是一种在治疗肥胖症中用作辅剂的厌食剂。它表现出与安非他明相同的活性,但对CNS(中枢神经系统)和心血管系统具有较低的影响。因此它对于高血压患者、心脏病患者、糖尿病患者和老年人是优选的。
氟苯丙胺和D-氟苯丙胺是在治疗肥胖症中用作辅剂的厌食剂,它表现出精神刺激的效果。
苯氟雷司是一种降血胆甾醇和降甘油三酯试剂,它也表现出厌食和降血糖活性。
积雪草是一种用于治疗前静脉曲张症的淡的利尿剂、抗风湿病剂和外围血管舒张剂。
胰酶IX F.U.是用于治疗胰腺不足的完全冻干的胰腺。
甲福明是一种用于治疗糖尿病,特别是肥胖病人的糖尿病的降血糖剂。已经证明甲福明在脂类代谢和降低体重以及对糖尿病肥胖病人的厌食活性方面呈阳性影响。
脱氢胆酸钠是一种稀胆汁排泄剂,它引起低密度的胆汁分泌。
熊去氧胆酸是用于液化胆汁的试剂。它也具有抗胆固醇的活性。
硒是用作自由基清除剂的一种元素。它也用于防止Kershan病并且在化学疗法中用作辅剂。
可立宁是一种交感神经阻滞剂又是一种散瞳剂。它已用于治疗阳萎。
维生素A用于治疗维生素缺乏症、脂类吸收障碍、营养不良症并用于治疗皮肤病。
维生素B1用于维生素B1缺乏症的治疗和预防,用于治疗妊辰充血症和由烟酸缺乏症和怀孕期间所引起的神经炎。
维生素B6用于维生素B6缺乏症的治疗和预防,用于治疗贫血症、痉挛、以及在外围神经炎的预防中的妊辰和辐射充血症。
维生素E用于治疗维生素缺乏症、脂类吸收障碍和用作早产婴儿的抗氧化剂。
维生素C用于治疗维生素C缺乏症。
三碘代三重乙酸是一种甲状腺激素,具有分解脂肪的活性。
苯双甲吗啉重酒石酸酯和苯双甲吗啉双羟萘酸酯是拟交感神经剂。它们也表现出中枢厌食活性。
该药物组合物和剂量将随着被治疗病人的情况而变化。因此,特定的剂量应该根据病人的需要和根据管理或监督上述组合物用药的人的职业判断来调整。该剂量可一次服用或可分成若干小剂量在不同的间隔时间内服用。
将已被选用的所述试剂以一种协同的方式结合以便改善它们的单独的药性,并且同时彼此之间不相互影响。
由所述药物组合物所提供的优点是避免或处理了上面所提到的在饮食中由于缺乏碳水化合物而引起的副作用。
此外,通过按照本发明的食品组合物和药物组合物结合的方式,使得人们总是可以在减少体重的同时不必忍受缺乏食物例如面条、面包和烤制食品的痛苦。
本发明的药物组合物还可以另外含有赋形剂和在需要的情况下的任意的其它辅助剂。
本发明的组合物可以按不同的药物配方进行配制,其精确性依赖于所选择的配制途径。
因此,口服用药的固体组合物包括片剂、可分散粉末、颗粒和胶囊。
在片剂中,活性成份是与,至少一种惰性的稀释剂如乳糖、淀粉、甘露醇、微晶纤维素或磷酸钙;粒化和破碎剂例如谷物淀粉、明胶、微晶纤维素或聚乙烯吡咯烷酮;润滑剂如硬脂酸镁、硬脂酸或滑石,相混合。该片剂可用已知的技术进行包裹以延迟在胃肠道内的破碎和吸收作用,并且提供了很长时间的持续作用。胃膜的包裹或肠膜的包裹可用糖、明胶、羟基丙基纤维素或丙烯酸树脂。
口服用的配方也可以是可吸收材料例如明胶的硬胶囊,其中的活性成分与惰性稀释剂和润滑剂混合,或是与糊状物例如乙氧基化的饱和的甘油酯混合。
软胶囊是可以的,其中的活性成份与水或一种油性介质如花生油、液体石蜡油或橄榄油混合。
通过加入水而适于悬浮液制备的可分散粉末和颗粒提供与分散剂或湿润剂,悬浮剂如羰基甲基纤维素钠、藻酸钠、聚乙烯吡咯烷酮、黄耄胶、黄原胶、阿拉伯树胶和一种或多种防腐剂如对羟基苯甲酸的甲酯或正丙酯,相混合的活性成份。另外也可存在赋形剂如甜味剂、风味剂和着色剂。
口服用药的液体组合物包括乳剂、溶液、悬浮剂、浆剂和含有普遍使用的惰性稀释剂如蒸溜水、乙醇、山梨醇、甘油或丙二醇的西也剂。这些组合物可以含有辅剂如湿润剂、悬浮剂、甜味剂、风味剂、芳香剂、防腐剂和缓冲剂。
本发明的药物组合物也可以以用于药物的直肠用药的栓剂形式用药。
用药的剂量和次数可根据病人的症状、年龄和体重以及用药的途经而定,但通常本发明的组合物可以进行口服用药,剂量为对于平均体重70千克的病人每天用药7-23克。
上述组合物可以用成套包的形式制备。所述成套包可以包含该组合物或者其组分,例如,以不同胶囊的形式分别制备。按照这种方式可以将不同的化合物结合和/或根据所治疗病人采用不同的剂量。
因此本发明的进一步的目的是如权利要求书中所陈述的连续、同时或分别用药的成套包部分。
具体实施方式
按照本发明的食品组合物、方法和药物组合物将通过参考下面所提供的实施例而得到进一步的描述,这些实施例仅仅是对本发明的非限定性的说明,其中所述的百分比可理解为总干基重量的重量百分比。
实施例1
小麦面筋 55%
小麦纤维 40%
蔬菜纤维 5%
小麦面筋是由各公司,例如意大利的Rocchetta公司市售的产品。
蔬菜纤维是例如西红柿、菠菜、洋葱等的纤维,这些纤维产品是由包括意大利的新食品公司(Newfood)在内的各公司市售的。
实施例2
小麦面筋 35%
大豆蛋白 20%
小麦纤维 45%
实施例3
小麦面筋 35%
水果纤维 45%
大豆蛋白 20%
实施例4
小麦面筋 34%
小麦芽 33%
小麦纤维 17%
蔬菜纤维 16%
小麦芽是由不同的生产商,例如意大利的Rizzolio公司进行市售的产品。
实施例5
牛奶蛋白 10%
小麦纤维 15%
小麦芽 60%
水果纤维 15%
实施例6
将实施例1中的面粉制成面条。为达到此目的,将面粉与适量的水混合获得适于挤压成型的面团(约有20-30%的水)。将该面团通过适当的模挤压成意大利式细面条的形状,并且接着将该细面条在沸腾的盐水中煮熟,其所产生的感官特性完全类似于用高质量的粗粒硬质小麦粉制成的面条所产生的感官特性。
实施例7
将实施例2中的面粉制成面包。为达到此目的,将面粉与适量的水混合获得可成形的面团,并且向该面团中加入适量的面包酵母和盐。然后将该面团进行发酵约2小时,再合面并且最后在将其成形前放置约1小时,然后在烤炉中在220℃下烤制。
按照该种方式烤制的面包具有最佳的感官特性、表面硬度和脆度。
上述实施例中的面粉几乎是通用的并且在接着加入适量的附加配料后可以用于面条、鸡蛋面条、面包、面包棒、比斯可特(biscottes)、甜味和风味窝形奶油水果蛋糕、饼干等的生产。
在各种面粉间唯一可发现的区别在于其碳水化合物含量的不同,该碳水化合物的含量例如在按照实施例1的面粉中最低(确切为低于5%)并且在含有水果或蔬菜纤维的面粉中由于这些纤维中的残余的糖类而使碳水化合物的含量趋于较高(尽管总是低于15%)。
因此,如果一个人希望按照本发明的下列方法降低体重,他就应该开始使用如实施例1或2中的面粉,因为在这些面粉中糖类的含量可保证完全忽略。
一旦达到了理想的体重,这个人就可以将上面所提到的面粉与由于含有水果或蔬菜纤维而具有一定的,尽管是低的糖类含量的那些面粉(例如实施例3和4中的面粉)进行交替使用。
当这个人的体重和体形稳定下来时,他便可以将含有其它配料如牛奶蛋白、干肉或鱼动物蛋白、奶粉、乳酪粉、全蛋或干清蛋白或干蛋黄的面粉引入其饮食中。
在该后一阶段中,碳水化合物的含量应该总是维持在低于20重量%的水平。
应该指出的是按照本发明的面粉构成了想用本发明的方法消除过量体重来改善其体形的人们的摄入食品的基础。如果所有的以碳水化合物为基础的食物都用由按照本发明的面粉制成的类似的食物所代替的话,那么这个人就可以依然消费富含蛋白质和/或脂类(肉、鱼、熟食品、干酪)的各种食物而不必对摄入量有任何的限制,也不必以任何方式担心其结果或担心需要减掉多余的体重。
与迄今为止现有的低热量饮食方法相比本发明具有极大的优势,这些现有方法预示着一部分人要牺牲相当大的个人爱好,并且正是由于这个原因而使得这些人很难接受这些方法而达到满意的效果。
另外,由于不限制食物的摄入量,使得按照本发明的方法极其自由地消费不同的食物成为可能,这进一步使人们心甘情愿地满意地接受所推荐的饮食方法。
下面的实施例涉及按照本发明的药物组合物。下列组合物优选的是制成胶囊的形式。
实施例8
胶囊的制备。将下列成份任意与适量的赋形剂预混合以达到该胶囊的容量,然后填入该胶囊并封闭该胶囊。
安非拉酮氯化水合物 mg.20
芬氟拉明 mg.4
苯氟雷司 mg.50
三碘代三重乙酸 mg.0.4
胰酶IX F.U. mg.120
甲福明 mg.200
脱氢胆酸钠 mg.40
实施例9
两种胶囊A和B的制备,这两种胶囊是一成套包的部分,并且含有结合摄入的不同成份。
胶囊A
氟苯丙胺 mg.4
苯氟雷司 mg.50
胶囊B
三碘代三重乙酸 mg.0.8
胰酶IX F.U. mg.240
甲福明 mg.370
脱氢胆酸钠 mg.80
氯氮杂二钾盐 mg.2
实施例10
两种胶囊A和B的制备,这两种胶囊是一成套包的部分并且含有结合摄入的不同成份。
胶囊A
安非拉酮氯化水合物 mg.35
苯氟雷司 mg.150
维生素C mg.100
维生素E mg.100
维生素B6 mg.50
胶囊B
胰酶IX F.U mg.240
甲福明 mg.370
脱氢胆酸钠 mg.80
氯氮杂二钾盐 mg.4
Claims (13)
1.一种粉末状食品组合物,该组合物含有,以总干基重量计,至少50%的蛋白质,不超过20%的碳水化合物和30-50%的植物纤维。
2.按照权利要求1的食品组合物,其中碳水化合物的含量不超过15%。
3.按照权利要求2的食品组合物,其中碳水化合物的含量不超过5%。
4.按照权利要求1-3中任意一项的食品组合物,其中:
蛋白质选自由谷蛋白、大豆蛋白类、奶蛋白类、从肉或干鱼或熏鱼得到的动物蛋白类、蛋清和蛋黄、小麦蛋白类、麦芽、稻谷芽、大豆蛋白、豌豆蛋白所组成的组中;和
植物纤维选自包括谷类植物纤维类、蔬菜纤维类以及水果纤维类在内的组中;
所述食品组合物还非必须地含有
植物脂肪和/或动物脂类,和/或
面粉。
5.按照权利要求4的食品组合物,其中所述蛋白类为不含乳糖的豆奶,所述谷类植物纤维类为小麦、玉蜀黍和燕麦、玉蜀黍和大豆类,所述蔬菜纤维类为西红柿、菠菜、菊粉、阿拉伯胶,所述水果纤维为橙类和苹果类,所述植物脂肪为来自椰子和大豆的脂肪,动物脂类是蛋黄、奶油和全奶,以及所述面粉选自由嫩小麦粉和鼓小麦粉组成的组。
6.一种面条的替代食品,其中的面粉组分为按照权利要求1-4的任意一项的一种面粉。
7.一种面包或类似烤制品的替代食品,其中的面粉组分为按照权利要求1-4的任意一项的一种面粉。
8.一种非治疗目的的通过获得有利于美学观点的体重减轻来改善人的体形的方法,该方法包括从所说人的饮食中消除所有以碳水化合物为基础的食物,并且用按照权利要求1-4的任意一项的食品组合物制成的食物代替。
9.按照权利要求8的方法,其特征在于该方法包括:
初始阶段,在该阶段中用按照权利要求2的其中碳水化合物的含量低于5%的食品组合物制成的食物代替所说的以碳水化合物为基础的食物;
中间阶段,在该阶段中用按照权利要求2的其中碳水化合物的含量不高于15%的食品组合物制成的食物代替所说的以碳水化合物为基础的食物;
保持阶段,在该阶段中用按照权利要求1的食品组合物制成的食物代替所说的以碳水化合物为基础的食物。
10.按照权利要求1-4的食品组合物在制备用于体重减轻的药物中的应用。
11.按照权利要求10的应用,其中所述药物包括选自由镇静-安血剂、厌食剂和脂肪分解剂所组成的组中的至少一种辅剂。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP98830365.7 | 1998-06-16 | ||
EP98830365A EP0965278A1 (en) | 1998-06-16 | 1998-06-16 | Dietetic food composition and dietetic method using such composition |
EP99201794.7 | 1999-06-04 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1242237A CN1242237A (zh) | 2000-01-26 |
CN100388951C true CN100388951C (zh) | 2008-05-21 |
Family
ID=8236684
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB99108490XA Expired - Fee Related CN100388951C (zh) | 1998-06-16 | 1999-06-16 | 饮食食品组合物和利用该组合物的饮食方法 |
Country Status (9)
Country | Link |
---|---|
EP (3) | EP0965278A1 (zh) |
JP (1) | JP2000063286A (zh) |
CN (1) | CN100388951C (zh) |
AT (2) | ATE296546T1 (zh) |
DE (2) | DE69925538T2 (zh) |
DK (2) | DK0965351T3 (zh) |
ES (2) | ES2241234T3 (zh) |
HK (1) | HK1024869A1 (zh) |
PT (1) | PT965351E (zh) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2788409B1 (fr) * | 1999-01-19 | 2002-10-11 | Cie Europ De Produits Dietetiq | Gateau hyperprotidique hypocalorique |
WO2001064056A1 (en) * | 2000-03-03 | 2001-09-07 | Istituto Erboristico L'angelica S.P.A. | High protein content pasta and energy-restricted food preparation including said pasta |
AU6447900A (en) * | 2000-06-14 | 2001-12-24 | Reginald Allouche | Low-calorie and high-protein cakes |
US20030138547A1 (en) | 2002-01-22 | 2003-07-24 | Mars, Incorporated | Weight management system for animals |
ITMI20021362A1 (it) * | 2002-06-20 | 2003-12-22 | Biava Pier Mario | Impiego di un estratto embrionale animale come sostanza nutriente e integratore dietetico-nutraceutico |
US20050054731A1 (en) * | 2003-09-08 | 2005-03-10 | Franco Folli | Multi-system therapy for diabetes, the metabolic syndrome and obesity |
AU2004281184C1 (en) * | 2003-10-16 | 2012-01-12 | Techcom Group, Llc | Reduced digestible carbohydrate food having reduced blood glucose response |
GB2410414A (en) * | 2004-01-27 | 2005-08-03 | Stuart Dudley | Low carbohydrate flour |
US8075932B2 (en) | 2004-03-04 | 2011-12-13 | Hiroshi Araki | Fermented food and its preparation |
JP4790666B2 (ja) * | 2007-06-15 | 2011-10-12 | 鳥越製粉株式会社 | パン様食品素材およびこれを用いたパン様食品 |
EP2395857B1 (en) | 2009-02-15 | 2016-07-13 | Cargill, Incorporated | Citrus pulp fiber systems and gel-based dessert systems |
CN102669553A (zh) * | 2012-05-04 | 2012-09-19 | 蓝照斓 | 一种黍米保健面条 |
CN102687742A (zh) * | 2012-06-11 | 2012-09-26 | 陕西师范大学 | 苹果肉纤维蛋糕及其制备方法 |
CN103584125A (zh) * | 2013-10-18 | 2014-02-19 | 宿州市皖神面制品有限公司 | 一种百合保健功能谷朊粉的加工方法 |
JP6231360B2 (ja) * | 2013-11-22 | 2017-11-15 | 千葉製粉株式会社 | 中華麺用の食感改良剤、中華麺、および、中華麺の製造方法 |
WO2022004126A1 (ja) * | 2020-06-30 | 2022-01-06 | ベースフード株式会社 | 麺および麺の製造方法 |
CN112245409B (zh) * | 2020-10-23 | 2022-03-15 | 安徽大学 | 一种植物蛋白-熊去氧胆酸缓释纳米粒复合微囊及其制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4042714A (en) * | 1975-10-20 | 1977-08-16 | Pfizer Inc. | Polydextrose-based farinaceous compositions |
US5106634A (en) * | 1989-09-11 | 1992-04-21 | Clovis Grain Processing, Ltd. | Process for the co-production of ethanol and an improved human food product from cereal grains |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS51109773A (ja) * | 1975-03-20 | 1976-09-28 | Mitsubishi Electric Corp | Handotaisochi |
JP2700850B2 (ja) * | 1986-03-31 | 1998-01-21 | 株式会社 ミドリ十字 | 栄養食品 |
JPH05112565A (ja) * | 1991-06-27 | 1993-05-07 | Takasago Internatl Corp | ヨヒンビンスルホナート誘導体及びこれを含有するアドレナリン拮抗剤 |
JPH0672861A (ja) * | 1992-07-09 | 1994-03-15 | Takeda Chem Ind Ltd | 着色固形製剤 |
LU88373A1 (fr) * | 1993-07-12 | 1994-04-01 | Michel Urso Prof Medecin Et Ch | Produit pour maigrir |
US6379714B1 (en) * | 1995-04-14 | 2002-04-30 | Pharmaprint, Inc. | Pharmaceutical grade botanical drugs |
JPH1171285A (ja) * | 1997-06-30 | 1999-03-16 | Chugai Pharmaceut Co Ltd | スクラルファート含有組成物及びその製造方法 |
DE69833000T2 (de) * | 1997-09-26 | 2006-09-07 | Noven Pharmaceuticals, Inc., Miami | Bio-klebemittelzusammensetzungen |
-
1998
- 1998-06-16 EP EP98830365A patent/EP0965278A1/en not_active Withdrawn
-
1999
- 1999-06-04 PT PT99201794T patent/PT965351E/pt unknown
- 1999-06-04 DK DK99201794T patent/DK0965351T3/da active
- 1999-06-04 DK DK02078716T patent/DK1269860T3/da active
- 1999-06-04 AT AT99201794T patent/ATE296546T1/de not_active IP Right Cessation
- 1999-06-04 EP EP99201794A patent/EP0965351B1/en not_active Expired - Lifetime
- 1999-06-04 AT AT02078716T patent/ATE307497T1/de not_active IP Right Cessation
- 1999-06-04 DE DE69925538T patent/DE69925538T2/de not_active Expired - Lifetime
- 1999-06-04 ES ES99201794T patent/ES2241234T3/es not_active Expired - Lifetime
- 1999-06-04 ES ES02078716T patent/ES2247264T3/es not_active Expired - Lifetime
- 1999-06-04 EP EP02078716A patent/EP1269860B1/en not_active Expired - Lifetime
- 1999-06-04 DE DE69928027T patent/DE69928027T2/de not_active Expired - Lifetime
- 1999-06-16 JP JP11170005A patent/JP2000063286A/ja active Pending
- 1999-06-16 CN CNB99108490XA patent/CN100388951C/zh not_active Expired - Fee Related
-
2000
- 2000-06-21 HK HK00103774A patent/HK1024869A1/xx not_active IP Right Cessation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4042714A (en) * | 1975-10-20 | 1977-08-16 | Pfizer Inc. | Polydextrose-based farinaceous compositions |
GB1508940A (en) * | 1975-10-20 | 1978-04-26 | Pfizer | Polydextrose-based farinaceous compositions |
US5106634A (en) * | 1989-09-11 | 1992-04-21 | Clovis Grain Processing, Ltd. | Process for the co-production of ethanol and an improved human food product from cereal grains |
Non-Patent Citations (2)
Title |
---|
Retrieved from the internet guide to our products-singles,combinations &chinese. XP002135817. 1998 |
Retrieved from the internet guide to our products-singles,combinations &chinese. XP002135817. 1998 * |
Also Published As
Publication number | Publication date |
---|---|
PT965351E (pt) | 2005-08-31 |
DE69925538D1 (de) | 2005-07-07 |
DE69928027T2 (de) | 2006-04-20 |
JP2000063286A (ja) | 2000-02-29 |
ATE296546T1 (de) | 2005-06-15 |
DE69925538T2 (de) | 2005-10-27 |
ATE307497T1 (de) | 2005-11-15 |
EP0965278A1 (en) | 1999-12-22 |
DK0965351T3 (da) | 2005-07-04 |
EP1269860B1 (en) | 2005-10-26 |
ES2247264T3 (es) | 2006-03-01 |
EP0965351A2 (en) | 1999-12-22 |
ES2241234T3 (es) | 2005-10-16 |
CN1242237A (zh) | 2000-01-26 |
EP0965351A3 (en) | 2000-06-21 |
DK1269860T3 (da) | 2005-12-19 |
EP1269860A1 (en) | 2003-01-02 |
HK1024869A1 (en) | 2000-10-27 |
EP0965351B1 (en) | 2005-06-01 |
DE69928027D1 (de) | 2005-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100388951C (zh) | 饮食食品组合物和利用该组合物的饮食方法 | |
JP5189945B2 (ja) | ダイエット組成物及びそれを用いるダイエット食品及びペットフードの製造方法 | |
JP5109117B2 (ja) | スダチ由来の組成物、並びに当該組成物を含有する医薬組成物、健康飲食品及びサプリメント | |
US6322826B2 (en) | Dietetic food composition and dietetic method using such composition | |
US6569483B2 (en) | Dietetic food composition and dietetic method using such composition | |
EP0930019A2 (en) | Composition for treating obesity and foods and drinks containing the same | |
CN101755872A (zh) | 适用于糖尿病人食用的糕点组分 | |
KR100666054B1 (ko) | 구아바 식물성분을 함유한 찐빵 및 그 제조방법 | |
CN109430344A (zh) | 一种具有健胃消食功能的杂粮茯茶饼干及其制备方法 | |
KR100966719B1 (ko) | 와송 추출물을 포함하는 비만 억제 및 고지혈증 예방 또는치료용 조성물 | |
US6210702B1 (en) | Weight loss composition and method for losing weight | |
CN104397542A (zh) | 一种小米首乌粥 | |
CN110810827A (zh) | 一种供高血糖人群食用的营养均衡食品组合物 | |
US20020098175A1 (en) | Dietetic food composition and dietetic method using such composition | |
KR100237974B1 (ko) | 상백피를 주성분으로 함유하는 당뇨환자용 과자류 조성물 | |
KR100481114B1 (ko) | 바나바, 호로파 및 여주 추출물의 발효물을 유효성분으로함유하는 혈당강하용 약학적 조성물 | |
CN101773248A (zh) | 以桑籽粉为有效成分的调节血糖保健食品 | |
CN106616321A (zh) | 一种健康养生的方便烩面的制作方法 | |
KR101344564B1 (ko) | 마라소스의 주성분인 고추 및 화초 추출물을 유효성분으로 함유하는 비만 또는 고지혈증 예방 및 치료용 조성물 | |
CN112493284A (zh) | 一种含有高蛋白和高膳食纤维的粗粮饼干及其制备方法 | |
KR20060002108A (ko) | 한천을 이용한 즉석 저열량 식품의 조성물 및 이의 제조방법 | |
CN105394134A (zh) | 一种高蛋白质减肥饼干及其制备工艺 | |
US8075932B2 (en) | Fermented food and its preparation | |
JP3897262B2 (ja) | キヌア皮含有組成物及び食品 | |
US20070141119A1 (en) | Use of additionally fermented distillers grains for preventing and/or treating increased blood sugar values |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080521 Termination date: 20120616 |